Thermomind Overview
ThermoMind is a cutting-edge technology company that is revolutionizing the healthcare industry by offering advanced thermal imaging solutions. Using the latest in thermal sensing technology and artificial intelligence, the company is dedicated to providing highly accurate and reliable imaging technologies that can help doctors and medical professionals make more informed decisions about patient care. The company develops medical devices with customized, highly sensitive thermal sensing hardware and combines with sophisticated AI system to analyze thermal data and identify potential health issues in patients. Whether it's for early disease detection, real-time monitoring, or ongoing patient care, the company's imaging solutions offer unparalleled accuracy and reliability. The current target of the company is transforming the way breast cancer is detected and diagnosed, by a next-generation non-contact and radiation-free screening modality for breast cancer detection. The core of the technology is the advanced AI analysis which is set to identify metabolic abnormalities within the breast indicating breast cancer. The startup's screening modality is designed to be highly scalable, efficient, and cost-effective, making it accessible to a wide range of patients and healthcare providers. By eliminating the need for radiation and contact-based screening methods, the company's technology offers a safer and more comfortable screening experience for patients, while also reducing the risk of false positives and unnecessary biopsies.
Cumulative Funding Raised Over Time ($)
$620KAug 2021
Latest News
growth-positive
Cancer screening: Dr. Larisa Adamyan & Najeeb Ayoub - ISRAEL21c
ThermoMind, a healthcare company, has won a Horizon grant of 11.5m euro from the European Commission. They are developing a novel, noninvasive, radiation-free and patient-centric modality called ThermoMind, which aims to revolutionize breast cancer screening. The technology also has the potential to detect and diagnose other diseases that impact metabolic functions. The companys objective is to enhance the overall health and wellbeing of individuals by improving the standard of care for breast cancer detection. ThermoMinds approach could increase the chances of successful treatment, improve patient monitoring, and reduce discomfort and anxiety associated with traditional diagnostic methods. The founders, Najeeb and Larisa, are focused on creating employment opportunities and generating novel forms of data in the healthcare industry.
Investment
growth-positive
Safe, painless early breast-cancer detection is on the way - ISRAEL21c
Israeli startup ThermoMind is developing a thermal-sensor-based, contact-free, radiation-free screening modality for detecting early-stage breast tumors. The company is conducting clinical trials with 15 ThermoBreast devices in 11 hospitals across the US, Europe, and Israel. ThermoMinds technology uses infrared sensors developed by SCD for thermal imaging in healthcare. The AI-based thermal image decision support system can detect metabolic and vascular changes caused by cancer within minutes. ThermoMind was founded by Najeeb Ayoub and Larisa Adamyan, who are also a couple. They moved to Israel to start the company and have received a grant of 11.5 million euros from Horizon Europe.
Customers
growth-positive
ThermoMind developing non-invasive early-stage breast cancer detection
ThermoMind, a Haifa-based medical technology start-up, aims to develop a medical device for early-stage breast cancer detection. The company received an 11.6 million Euro grant from Horizon Europe for a clinical study at twelve sites in Israel, Europe, and the United States. ThermoMind was founded in Israel in April 2022 and formed a consortium with eighteen partners, including leading hospitals and research institutes. The company plans to have its product on the market in two years. ThermoMinds thermal scanning device uses high-resolution infrared sensors to capture breast thermograms and analyzes them using advanced artificial intelligence algorithms. The technology is risk-free, non-invasive, and comfortable for patients. ThermoMinds innovation in thermal imaging for breast cancer detection sets new protocols and standards for the modality.
InvestmentPartnersCustomers
growth-positive
סריקה לא פולשנית לזיהוי סרטן השד
Israeli start-up ThermoMind is developing an artificial intelligence (AI) enhanced thermography technology for early detection of breast cancer. The technology identifies abnormal patterns in blood supply and metabolism in the breast area that occur due to the development of cancer cells. The scan is non-invasive and does not require contact with the human body. The company has received a grant of 11.5 million euros from the European Union and has recently applied for a grant from the Chief Scientist for the sake of innovation, hoping to raise an additional million dollars for development next year.
InvestmentExpand
growth-positive
'Fewer women on operating table': New Israeli technology battling breast cancer
Prof. Regina Barzilay from MIT has developed an AI algorithm named Mirai that analyses mammogram x-rays and detects early signs of breast cancer. The system has analyzed nearly 130,000 mammograms and has a success rate twice that of the current system used to assess mammograms. The system is undergoing clinical trials in several countries, including Israel, in partnership with Maccabi Healthcare Services and Assuta Hospital. The AI system is considered a gamechanger in predicting womens risk of developing breast cancer and could help to improve detection and treatment of the disease.
CustomersPartnersExpand
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $12.62M |
| Last funding | $12M |
| Stage | Pre-Seed |
| Rounds | 2 |
| Investors | 0 |
Team Members
2
Employees: 1-10
Web & Social Links
| Website | www.thermomind.io |
Locations
Ha-Namal St 33, Haifa, Israel
Photos & Videos
3 item(s)
Thermomind Business
Business models
B2B, B2G
Product stage
Clinical Trial
Employees
1-10
Sector
Health Tech & Life SciencesDigital HealthcareDigital Medical DiagnosticsMedical DevicesDiagnostics DevicesTarget Customer
Healthcare & Life SciencesHealthcareProvidersPatientsCore Technology
Artificial IntelligenceSensingInfraredTags (10)
cancerwomen-healthmedical-technologiesnon-invasiveearly-detectiondigital-healthcareartificial-intelligencemedical-devicesfemtechcancer-diagnosticsGeographic Markets
United Arab EmiratesEuropeIsraelUnited StatesAmericasThermomind Financials
$12.62M
Total funding
Undisclosed
Capital raised
$12M
Last funding
Pre-Seed
Funding stage
2
Total rounds
0
Investors
Cumulative Funding Raised Over Time ($)
$620KAug 2021
Private Equity Funding
Pre-Seed
Aug 2021
$620K
Non-Equity Funding
GrantEvent
Aug 2022
$12M
European Commission (Lead)
Thermomind Lifecycle
Cumulative Funding Raised Over Time
$620KAug 2021
All Events
Pre-Seed
Aug 2021
$620K
GrantEvent
Aug 2022
$12M
European Commission (Lead)
Programs & Community Involvement
NVIDIA Inception
HiVentures
Thermomind News
6 articles
growth-positive
Cancer screening: Dr. Larisa Adamyan & Najeeb Ayoub - ISRAEL21c
ThermoMind, a healthcare company, has won a Horizon grant of 11.5m euro from the European Commission. They are developing a novel, noninvasive, radiation-free and patient-centric modality called ThermoMind, which aims to revolutionize breast cancer screening. The technology also has the potential to detect and diagnose other diseases that impact metabolic functions. The companys objective is to enhance the overall health and wellbeing of individuals by improving the standard of care for breast cancer detection. ThermoMinds approach could increase the chances of successful treatment, improve patient monitoring, and reduce discomfort and anxiety associated with traditional diagnostic methods. The founders, Najeeb and Larisa, are focused on creating employment opportunities and generating novel forms of data in the healthcare industry.
Investment
growth-positive
Safe, painless early breast-cancer detection is on the way - ISRAEL21c
Israeli startup ThermoMind is developing a thermal-sensor-based, contact-free, radiation-free screening modality for detecting early-stage breast tumors. The company is conducting clinical trials with 15 ThermoBreast devices in 11 hospitals across the US, Europe, and Israel. ThermoMinds technology uses infrared sensors developed by SCD for thermal imaging in healthcare. The AI-based thermal image decision support system can detect metabolic and vascular changes caused by cancer within minutes. ThermoMind was founded by Najeeb Ayoub and Larisa Adamyan, who are also a couple. They moved to Israel to start the company and have received a grant of 11.5 million euros from Horizon Europe.
Customers
growth-positive
ThermoMind developing non-invasive early-stage breast cancer detection
ThermoMind, a Haifa-based medical technology start-up, aims to develop a medical device for early-stage breast cancer detection. The company received an 11.6 million Euro grant from Horizon Europe for a clinical study at twelve sites in Israel, Europe, and the United States. ThermoMind was founded in Israel in April 2022 and formed a consortium with eighteen partners, including leading hospitals and research institutes. The company plans to have its product on the market in two years. ThermoMinds thermal scanning device uses high-resolution infrared sensors to capture breast thermograms and analyzes them using advanced artificial intelligence algorithms. The technology is risk-free, non-invasive, and comfortable for patients. ThermoMinds innovation in thermal imaging for breast cancer detection sets new protocols and standards for the modality.
InvestmentPartnersCustomers
growth-positive
סריקה לא פולשנית לזיהוי סרטן השד
Israeli start-up ThermoMind is developing an artificial intelligence (AI) enhanced thermography technology for early detection of breast cancer. The technology identifies abnormal patterns in blood supply and metabolism in the breast area that occur due to the development of cancer cells. The scan is non-invasive and does not require contact with the human body. The company has received a grant of 11.5 million euros from the European Union and has recently applied for a grant from the Chief Scientist for the sake of innovation, hoping to raise an additional million dollars for development next year.
InvestmentExpand
growth-positive
'Fewer women on operating table': New Israeli technology battling breast cancer
Prof. Regina Barzilay from MIT has developed an AI algorithm named Mirai that analyses mammogram x-rays and detects early signs of breast cancer. The system has analyzed nearly 130,000 mammograms and has a success rate twice that of the current system used to assess mammograms. The system is undergoing clinical trials in several countries, including Israel, in partnership with Maccabi Healthcare Services and Assuta Hospital. The AI system is considered a gamechanger in predicting womens risk of developing breast cancer and could help to improve detection and treatment of the disease.
CustomersPartnersExpand
growth-positive
15 מיליון אירו: החוקרים הישראלים שמנסים לנצח את הסרטן
Israeli startup ThermoMind Ltd has received a total grant of 11.5 million euros, including 3.115 million euros from Israels budget, for a four-year project. The company has developed a new scanning technology capable of detecting disturbances in blood vessels caused by tumors. The technology combines new infrared cameras, which can identify minute temperature differences, with artificial intelligence algorithms for efficient analysis of thermal patterns. The grant will enable the company to conduct an international clinical study to promote this breakthrough technology.
Investment
Thermomind Team
Employee Info
| Employees (range) | 1-10 |
| Exact count | 1 |
| Team members | 2 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 11 classification IDs that could be used for matching.
Thermomind Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 98/100 |
| Missing | markets |
| BI Verification | Yanina Wainscheinker |
| Registrar ID | 516593407 |
| Creator | Najeeb Ayoub |
| Creator email | najeeb@thermomind.io |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2023-10-11T00:00:00.000Z |
| Created | 2022-08-10T00:00:00.000Z |
| Claimed | Yes |